Immediate Impact
56 standout
Citing Papers
Efficacy and Safety of Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss Among Adults Without Diabetes
2025 Standout
Metabolic Dysfunction–Associated Steatotic Liver Disease (MASLD) in People With Diabetes: The Need for Screening and Early Intervention. A Consensus Report of the American Diabetes Association
2025 Standout
Works of Arvid Jungnik being referenced
Phase I studies of the safety, tolerability, pharmacokinetics and pharmacodynamics of the dual glucagon receptor/glucagon‐like peptide‐1 receptor agonist BI 456906
2022
Author Peers
| Author | Last Decade | Papers | Cites | ||||
|---|---|---|---|---|---|---|---|
| Arvid Jungnik | 206 | 120 | 54 | 119 | 14 | 415 | |
| L. T. Tenconi | 91 | 116 | 55 | 47 | 18 | 490 | |
| Christine Reynolds | 86 | 91 | 15 | 57 | 15 | 410 | |
| Stuart Mair | 63 | 110 | 49 | 77 | 25 | 398 | |
| Aziz Laurent | 112 | 57 | 18 | 127 | 15 | 412 | |
| Helen Gu | 100 | 117 | 64 | 49 | 18 | 500 | |
| Ed J. Hendricks | 144 | 112 | 17 | 61 | 13 | 446 | |
| Ming-Yi Zhou | 224 | 55 | 26 | 82 | 19 | 432 | |
| Loretta M. Byrne | 142 | 81 | 21 | 40 | 12 | 385 | |
| W A McAllister | 43 | 46 | 68 | 119 | 11 | 487 | |
| Jean‐Marc Lobaccaro | 99 | 104 | 41 | 120 | 12 | 436 |
All Works
Loading papers...